1.54
0.00 (0.00%)
| Penutupan Terdahulu | 1.54 |
| Buka | 1.56 |
| Jumlah Dagangan | 2,129,567 |
| Purata Dagangan (3B) | 1,821,640 |
| Modal Pasaran | 592,230,720 |
| Harga / Jualan (P/S) | 4.60 |
| Harga / Buku (P/B) | 0.920 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2025 |
| Margin Keuntungan | -78.24% |
| Margin Operasi (TTM) | -29.42% |
| EPS Cair (TTM) | -0.320 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -14.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 118.03% |
| Nisbah Semasa (MRQ) | 6.12 |
| Aliran Tunai Operasi (OCF TTM) | -111.26 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -59.87 M |
| Pulangan Atas Aset (ROA TTM) | -11.63% |
| Pulangan Atas Ekuiti (ROE TTM) | -25.73% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Menurun |
| Medical Devices (Global) | Bercampur | Menurun | |
| Stok | Standard BioTools Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | 0.0 |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | -1.80 |
|
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.53% |
| % Dimiliki oleh Institusi | 73.09% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| CAREY THOMAS D. | 1.17 | - | 51,282 | 60,000 |
| CASDIN ELI | 1.17 | - | 52,991 | 61,999 |
| COX TROY | 1.17 | - | 57,264 | 66,999 |
| EGHOLM MICHAEL | - | 1.11 | -66,127 | -73,401 |
| KIM HANJOON ALEX | - | 1.11 | -12,740 | -14,141 |
| MACKAY SEAN | - | 1.11 | -19,661 | -21,824 |
| Jumlah Keseluruhan Kuantiti Bersih | 63,009 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 79,632 | |||
| Purata Pembelian Keseluruhan ($) | 1.17 | |||
| Purata Jualan Keseluruhan ($) | 1.11 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| CAREY THOMAS D. | Pengarah | 26 Feb 2026 | Diperolehi (+) | 51,282 | 1.17 | 60,000 |
| COX TROY | Pengarah | 26 Feb 2026 | Diperolehi (+) | 57,264 | 1.17 | 66,999 |
| CASDIN ELI | Pengarah | 26 Feb 2026 | Diperolehi (+) | 52,991 | 1.17 | 61,999 |
| KIM HANJOON ALEX | Pegawai | 23 Feb 2026 | Dibuang (-) | 12,740 | 1.11 | 14,141 |
| MACKAY SEAN | Pegawai | 23 Feb 2026 | Dibuang (-) | 19,661 | 1.11 | 21,824 |
| EGHOLM MICHAEL | Pegawai | 23 Feb 2026 | Dibuang (-) | 66,127 | 1.11 | 73,401 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 30 Jan 2026 | Pengumuman | Standard BioTools Completes Sale of SomaLogic to Illumina |
| 08 Jan 2026 | Pengumuman | Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |